Akantior

polihexanide · SIFI SPA
ORPHAN AUTHORISED IN THE EU

What Akantior is used for

Akantior is indicated for the treatment of Acanthamoeba keratitis in adults and children from 12 years of age.

Approved use, as published by the European Medicines Agency.

What the labels mean

  • Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).

Key facts

Brand
Akantior
Active substance
polihexanide
Disease area
Acanthamoeba Keratitis
Medicine group
Ophthalmologicals
ATC code
S01AX24
Marketing authorisation holder
SIFI SPA
Authorised in the EU since
2024

Official information

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Akantior used for?

Akantior is indicated for the treatment of Acanthamoeba keratitis in adults and children from 12 years of age.

What is the active substance in Akantior?

Akantior contains polihexanide.

Who makes Akantior?

The EU marketing authorisation holder is SIFI SPA.

Is Akantior an orphan medicine?

Yes. Akantior is designated an orphan medicine in the EU, for a rare disease (Acanthamoeba Keratitis).

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.